| First Author | Weng CC | Year | 2019 |
| Journal | Oncogene | Volume | 38 |
| Issue | 12 | Pages | 2005-2019 |
| PubMed ID | 30467381 | Mgi Jnum | J:349042 |
| Mgi Id | MGI:7645991 | Doi | 10.1038/s41388-018-0575-7 |
| Citation | Weng CC, et al. (2019) Mutant Kras-induced upregulation of CD24 enhances prostate cancer stemness and bone metastasis. Oncogene 38(12):2005-2019 |
| abstractText | Prostate cancer (PCA), one of the most common malignant tumors in men, is the second leading cause of cancer deaths in males worldwide. We report here that PCA models harboring conditional LSL/Kras(G12D) or BRAF(F-V600E) allele with prostate-specific abrogated p53 function recapitulate human PCA precursor lesions, histopathology, and clinical behaviors. We found that the development of reprogrammed EMT-like phenotypes and skeleton metastatic behavior requires concurrent activated Kras and p53 depletion in PCA. Microarray analyses of primary PCA cells derived from these models identified several cancer stemness genes including CD24, EpCAM, and CD133 upregulated by KRAS(G12D). Among these stemness markers, we identified CD24 as a key driver of tumorigenesis and metastasis in vivo. These data demonstrate that specific factors involved in cancer stemness are critical for metastatic conversion of PCA and may be ideal targets for therapeutic intervention. |
